Back to News
Market Impact: 0.25
Allarity Gets Japanese Patent For Stenoparib DRP Companion Diagnostic; Protection Through 2039
Source: Nasdaq
Patents & Intellectual PropertyHealthcare & BiotechTechnology & Innovation
Allarity Therapeutics announced that the Japan Patent Office granted a key patent for its stenoparib-specific Drug Response Predictor companion diagnostic. The patent strengthens intellectual-property protection for Allarity's personalized cancer-treatment platform in Japan, though the announcement does not include clinical, revenue, or regulatory-approval data.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.35
Ticker Sentiment
ALLR0.75
More News
- China's AI leaders keep quiet despite U.S. 'publicity' on tech risks
- Karin Rådström is steering Daimler Truck in a new direction as the world’s biggest truckmaker faces a growing challenge from China
- AWS says it can't restore service to Bahrain, UAE facilities 6 months after Iran strikes
- Factbox-How AI leaders and world governments react to ’AI doom’ fears
- Chinese investors rush into US stocks as Beijing opens wider path overseas
- ‘The end of the keyboard is near’: Christian Klein predicts voice translation will be the next workplace advantage
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- Best AI Stock Research Tools for Professional Investors
- Weekly Update: Adding Live MBO Level 3 Data - Liquidity Heatmap, OFI Charts, and More